Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060268 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00060268 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 11 participants.
The verdict
NCT00060268, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have obstructive esophageal tumors.
Interventions
- DRUG HPPH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 1997-01 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060268
The ClinicalTrials.gov registry entry for NCT00060268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HPPH is the first listed.
NCT00060268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060268 about?
NCT00060268 is a clinical study titled "Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors". RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I/II trial to study the effectiv...
What is the current status of trial NCT00060268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 1997-01. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00060268?
The interventions under investigation include: HPPH (DRUG).
Who is sponsoring clinical trial NCT00060268?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.